88 results about "Surgical resection" patented technology

The invention provides a control system and method for an oral surgery robot, and relates to the field of intelligent control, and the method comprises the steps: firstly obtaining thin-layer CT scanning data covering neck and throat regions, constructing a throat three-dimensional model, then collecting a surgery view three-dimensional image through a 3D endoscope, and carrying out the 3D image collection; performing semantic-level dynamic registration based on visual features on the three-dimensional model of the throat, determining pose information of the oral surgical robot, outputting a next target pose point of the oral surgical robot in combination with the pose information and a pre-operative planned surgical resection path, and finally determining the target pose point of the oral surgical robot on the basis of the target pose point. And generating a joint control instruction of the oral surgical robot. Therefore, the navigation preparation time in the operation is shortened, the high consistency of the motion track of the mechanical arm and the focus resection path is ensured, and the track deviation risk caused by registration deviation of a traditional system can be fundamentally solved.

The invention relates to a hypertrophic obstructive cardiomyopathy virtual resection operation curative effect evaluation method based on individualized computational fluid mechanics, which can give visual postoperative hemodynamic indexes, predict postoperative curative effects, find an optimal resection scheme and realize preoperative accurate intelligent evaluation. Comprising the following steps of: acquiring coronary artery enhanced computed tomography image data, acquiring a coronary artery enhanced computed tomography image of a patient, and outputting and storing the coronary artery enhanced computed tomography image in a DICOM (Digital Imaging and Communications in Medicine) format; preprocessing image data, and segmenting and reconstructing a left ventricle-outflow tract structure three-dimensional model; setting a virtual excision scheme at the fleshy part; constructing a surgical resection model, and importing the model into finite element analysis software for solving; and the virtual postoperative curative effect is visualized. Verification and curative effect prediction of a patient excision scheme can be realized, and the operation success rate of a hypertrophic obstructive cardiomyopathy patient is improved.

The present invention discloses a fluorescent probe and its preparation method and application. The structural formula of the fluorescent probe of the present invention is: ‑ Cl ‑ Br ‑ , I ‑ The fluorescent probe of the present invention can rapidly undergo a bioorthogonal shear reaction to specifically activate fluorescence at the tumor site, thereby improving the imaging specificity of the target site. Simultaneously, the bioorthogonal coupling group of the probe is used to undergo biocoupling with cells, allowing the probe to be anchored on tumor cell membrane glycoproteins for long-term fluorescence imaging. The probe is suitable for non-invasive detection of tumors and surgical resection of tumors.

The present invention provides a generation method for a surgical resection-type sufficient radiation therapy dose plan for a large hepatocellular carcinoma. Assuming the principles of liver segmentectomy or hemihepatectomy principles when surgical liver resection is used to resect a liver tumor, a radiation therapy plan is generated using a liver region volume remaining after the assumed surgical resection as a target. The method specifically comprises: step 1, obtaining an original medical image; step 2, identifying a target region, a maximal dose region, and a remaining liver region from the original medical image, and obtaining a region identification result; step 3, obtaining a remaining liver region volume, and determining whether the remaining liver region volume is within a preset range; if the remaining liver region volume is not within the preset range, ending; otherwise, executing step 4; step 4, performing radiation therapy plan design on the basis of the region identification result and the original medical image, and obtaining a radiation therapy plan result. The maximum value of the preset range is 700 ml, and the minimum value is 300 ml. The present method can automatically implement radiation therapy plan generation.

A method and apparatus for the targeted delivery of chemotherapy to a surgical cavity, consisting of a triggered nanoparticle encapsulating a therapeutic agent and an energy delivery device that applied trigger energy to the surgical cavity. Following surgical removal of a cancerous tumor, the nanoparticle is administered, and the energy delivery device applies trigger energy to the surgical cavity and proximal tissue. The goal is the delivery of a therapeutic drug dose to cancerous and precancerous cells remaining after surgery, to prevent local tumor recurrence.

The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a neoadjuvant therapy comprising a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) in combination with radiation therapy (e.g., SBRT) or an anti-LAG-3 antibody (e.g., fianlimab) followed by surgical resection, and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the cancer is liver cancer, such as hepatocellular carcinoma (HCC).

The embodiment of the invention provides an organ tumor operation path planning method and system, electronic equipment and a storage medium, and belongs to the technical field of path planning, and the method comprises the steps: constructing a corresponding preoperative three-dimensional point cloud model based on a first image of a target organ obtained before an operation, constructing a corresponding intraoperative three-dimensional point cloud model based on a second target organ image scanned in the operation; carrying out registration on the preoperative three-dimensional point cloud model and the intraoperative three-dimensional point cloud model to obtain a registered target organ model; and inputting the target organ model into a preset path planning model, determining a necessary excision range, and determining a corresponding surgical excision path scheme based on the necessary excision range and a predetermined necessary reservation range. The embodiment of the invention aims to formulate a more accurate and safer surgical resection scheme, and the safety and reliability of subsequent actual target organ tumor surgery execution are guaranteed.

The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or abioequivalent thereof) as neoadjuvant therapy followed by surgical resection and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the liver cancer is hepatocellular carcinoma (HCC), the lung cancer is non-small cell lung cancer (NSCLC), or the head and neck cancer is head and neck squamous cell carcinoma (HNSCC).

A method for a method for treatment of cholangiocarcinoma (CCA) with cold atmospheric plasma and Folfirinox. The method includes treating a patient having CCA with a low dosage FOLFIRINOX regimen, for example, 6.73 nM, giving the patient the low-dosage FOLFIRINOX regimen pre-operatively, surgically removing the cancerous tumor from the patient, continuing the low-dosage FOLFIRINOX treatment regimen intra-operatively, applying cold atmospheric plasma to the surgical margins surrounding the area in the patient from which the tumor was removed, and continuing the FOLFIRINOX post-operatively.

The present invention discloses a system and a kit for diagnosing the natural regression of neuroblastoma, which relates to the technical field of medical diagnosis. The system and the kit provided by the present invention diagnose whether the tumor of a child with neuroblastoma in the Ms stage naturally regresses based on the read values of the target miRNA mature body and its isomers, and have high sensitivity and specificity, and can provide effective suggestions for clinical treatment on whether surgical resection is needed.

The invention discloses a system and a kit for diagnosing natural regression of neuroblastoma, and relates to the technical field of medical diagnosis. The system and the kit provided by the invention are used for diagnosing whether the tumor of the Ms-stage child neuroblastoma patient naturally fades or not on the basis of the reads values of the target miRNA mature body and the isomer thereof, have relatively high sensitivity and specificity, and can provide effective suggestions for whether surgical resection is needed or not for clinical treatment.

Indivi dualized neoantigen vaccines, as well as methods for their use in subjects to treat urothelial orbladder cancer are provided. In some embodiments, individualized neoantigen vaccines are used with an immune checkpoint inhibitor and optionally enfortumab vedotin to treat a urothelial or bladder cancer after surgical resection. Prior to surgical resection, in some embodiments, the subject is administered a neoadjuvant therapy comprising an immune checkpoint inhibitor, individualized neoantigen vaccines, and, optionally, enfortumab vedotin.

The invention discloses sodium alginate hydrogel of a chimeric antigen receptor NK cell for expressing catalase and application of the sodium alginate hydrogel. The hydrogel is formed by mixing endogenous calcium ion reactive hydrogel composed of HER1-CAR-CAT-NK and sodium alginate. After the hydrogel disclosed by the invention is injected into an operation excision part, HER1-CAR-CAT-NK cells are decomposed into oxygen by catalyzing main active oxygen (hydrogen peroxide) in a tumor, so that the tolerance of the cells to high-level oxidative stress and hypoxia in the tumor is improved, and the hydrogel shows obviously enhanced durability and effect functions in triple negative breast cancer, and therefore, the hydrogel can be used for preparing a medicine for treating the triple negative breast cancer. The local cell therapy not only can inhibit the growth of local primary residual tumors, but also can stimulate the whole-body anti-tumor activity and inhibit the growth of distant tumors. According to the present invention, the tumor oxidative stress and the anoxic microenvironment are remodeled through the ALG of HER1-CAR-CAT-NK so as to inhibit the postoperative recurrence of TNBC;

This disclosure provides methods for treating tumors, reducing tumor severity, inhibiting tumor growth, or inducing tumor necrosis, wherein the methods include: selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need of treatment and administering neoadjuvant therapy to the patient in a combination of a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) and radiation therapy (e.g., SBRT) or an anti-LAG-3 antibody (e.g., fenpromab), followed by surgical resection and optionally administration of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) as postoperative adjuvant therapy. In some embodiments, the cancer is liver cancer, such as hepatocellular carcinoma (HCC).

The present invention relates to a method for treating tumors or inhibiting tumor proliferation, comprising administering, as a neoadjuvant therapy, a therapeutically effective amount of a programmed death-ligand 1 (PD-L1) inhibitor (for example, an anti-PD-L1 antibody) to a cancer patient in need thereof, followed by surgical resection. In particular, the present invention relates to a method for administering a PD-L1 inhibitor as a neoadjuvant therapy prior to surgery to patients with surgically resectable upper gastrointestinal cancer, for example, localized gastric cancer, esophageal cancer or liver cancer. It has been identified that the administration of a PD-L1 inhibitor, particularly an anti-PD-L1 antibody, exhibits an excellent therapeutic effect as a neoadjuvant therapy for patients with surgically resectable localized gastric cancer, esophageal cancer, and liver cancer.

The present invention is directed to methods for detecting a melanoma, methods for determining whether a melanoma is stable or progressive, methods for evaluating the extent of surgery resection in a subject having a melanoma, and methods for determining a response by a subject having a melanoma to a therapy.

We disclose a composition, comprising a compound, comprising a melanin precursor that spontaneously synthesizes a melanin when in free form in vivo, and a peptide directly covalently bonded to or indirectly linked to the melanin precursor, wherein the direct covalent bond or indirect link of the peptide to the melanin precursor blocks spontaneous synthesis of the melanin in vivo in the absence of protease activity. We also disclose methods of tumor imaging, tumor detection, diagnosis, and treatment, including methods comprising administering, to a patient suffering from a tumor, the composition; and either surgically resecting the tumor or thermally ablating the tumor, wherein the surgical resection is guided at least in part by contrast imparted by, or the thermally ablating targets cells containing, the melanin, wherein the melanin is spontaneously synthesized in the tumor after administering the composition.

The present disclosure relates generally to cancer immunotherapies and, more particularly, to a polymer matrix delivery system for delivering a cancer adjuvant, especially for enhanced immunotherapy. More particularly, the disclosure relates to a polymer matrix delivery system for delivering a cancer adjuvant, comprising a biodegradable polymer; a cancer adjuvant; optionally, an immunomodulatory inorganic ion; and, a bulking agent, wherein the bulking agent is not a protein. An implant comprising the polymer matrix delivery system is also provided. A method of treating a solid tumor or the potential recurrence of a solid tumor comprising injecting the implant into the solid tumor or at a site of surgical resection of a solid tumor is also described.

The invention relates to the technical field of medical equipment, in particular to a surgical incision edge positioning and marking device which comprises a nail bin clamping plate and a nail abutting seat, a nail bin assembly is arranged on the nail bin clamping plate, and a nail pushing unit is arranged on the nail bin assembly. The nail pushing unit comprises a push rod with one end extending into a handle of the anastomat and an I-shaped tool bit which is arranged on the push rod and is used for cutting off mammary tissue and pushing a suture nail; the marking assembly comprises a marking unit and a feeding unit, wherein the marking unit is arranged on the I-shaped tool bit and used for marking and positioning the surgical cutting edge in the process that the I-shaped tool bit pushes the sewing nail, and the feeding unit is arranged on the I-shaped tool bit and used for conveying dye to the marking unit. And a drying assembly. According to the device, in the stitching nail anastomosis process, dye rolling and coating can be synchronously carried out on the preprocessed surface of a stitching nail, multiple colors can be selected, accurate judgment can be carried out in surgical cutting edge marking and positioning, more intuitive visual help is provided, and overall operation is easy and convenient.

The invention relates to a drug delivery system in a layered hybrid nanofiber structure containing chemotherapy drug and / or bioactive molecule, which can be applied locally in the pharmaceutical industry in the healthcare field, especially in the treatment of brain tumors, where long-term-regular drug release can be made, its production and use. The invention, in its most basic form, is a drug delivery system for local application in active ingredient loaded layered hybrid nanofiber structure which comprises PLA shell nanofibre layer with at least one active ingredient extract (10), PVA nanofiber layer loaded with at least one active ingredient (3), at least one active ingredient that electrosprayed (20) between said layers.

According to the radioactive hydrogel and the preparation method and application thereof and the radioactive tumor treatment application, chitosan serves as a matrix and is crosslinked with genipin to construct a three-dimensional network, and stable loading and slow release of radionuclides can be synchronously achieved; the self-antibacterial and adhesion characteristics of the patch can reduce the infection risk and ensure the fixation of the patch, so that a safe, effective and easy-to-operate local treatment platform is provided, the prepared patch can be directly placed on a tumor bed after resection in an operation, beta or alpha rays released by radionuclides accurately and continuously act on an area where tumor cells are most likely to remain, and the effect of treating the tumor cells is achieved. Different from traditional external radiation radiotherapy, the hydrogel can continuously release radiation with a low dosage rate. The mode has a stronger biological effect (such as inhibition of reproliferation) on tumor cells, the radiosensitivity difference of different cell periods and time phases can be overcome, the killing effect is more thorough, and chitosan is proved to have certain antibacterial activity, tumor cell growth inhibition activity and immunomodulatory activity. A synergistic effect can be generated with radionuclide, and a microenvironment which is not beneficial to survival and relapse of tumor cells is constructed together with the radionuclide.

The present invention relates to a 2-amino-substituted derivative (Formula I) or an ethylenediamine-substituted derivative (Formulas II and III) of hypocrellin as a photodynamic drug for treating the following tumors: esophageal cancer, gastric cancer, lung cancer, liver cancer, cholangiocarcinoma, colon cancer cells related to digestive tract tumors; brain cancer, head and neck cancer, tongue cancer, nasal cancer, oral cancer, glioblastoma cells related to head, neck and facial tumors; basal cell carcinoma, squamous cell carcinoma, cutaneous T-cell lymphoma, melanoma cells related to skin tumors; prostate cancer, bladder cancer cells related to genitourinary tumors. At the same time, such derivatives can localize the location of tumor tissues through their own fluorescence and are used for fluorescence-guided surgical resection of tumors.

A method, system, medium, and implementations for computer-aided preoperative surgical planning are described. Input data acquired with respect to a part of a patient is received by the system. The part corresponds to an organ, e.g., lung, of the patient to be operated on and includes one or more lesions to be removed during an operation. Then, an anatomic 3D model of the part of the patient is generated. Based on the generated anatomic 3D model, a preoperative plan for linear-cutting stapler resection of the one or more lesions from the organ to be carried out during the operation is obtained. The stapler cartridge size and the staple length are estimated based on the preoperative plan. Further, the resection based on the preoperative plan is visualized.

The application relates to a surgical rotary cutting system, comprising a rotary puncture device and a cutter device; the rotary puncture device comprises a puncture rod and a tissue fixing head arranged at one end of the puncture rod, the tissue fixing head is used for fixedly connecting with target tissue, and the puncture rod is used for driving the target tissue to rotate relative to the cutter device through the tissue fixing head; the cutter device comprises a cutting head, and the cutting head is used for cutting the target tissue into a continuous long strip structure. When the target tissue rotates, the cutter device which keeps the position unchanged can continuously cut the target tissue, so that the target tissue is cut into the continuous long strip structure. Finally, the long strip target tissue can be clamped to the outside of the abdominal wall at any position of the long strip structure through clamps, so that the target tissue does not need to be repeatedly clamped by the clamps for multiple times, and the operation is simple and efficient.

The invention discloses a method for constructing a liver injury animal model, which comprises the following steps: (a) providing a model animal, and completely anesthetizing the model animal; (b) the liver of the model animal is taken out, and the surgical resection proportion is determined; and (c) fixing the liver part needing to be cut by using a surgical suture line, and performing liver cutting. According to the method disclosed by the invention, the liver injury mouse model can be more efficiently constructed, and liver injury proportions required by different liver injury models can be met.

The present invention provides a multifunctional preoperative precise locator suitable for multiple organs, comprising a guide system and a positioning system. The guide system comprises a guide needle, a guide needle handle, a scale line, a rubber limiter, a sharp-tip needle core and a blunt-tip needle core. The tail end of the guide needle is connected to the guide needle handle. The positioning system comprises a micro-spring coil tube, a push rod buckle, a push rod, a push rod handle, a micro-spring coil, a tail line and a semi-push mark. The interior of the guide needle can be adapted to the micro-spring coil tube. The present invention improves the safety and ease of preoperative positioning for resection of small nodules in various organs in the body, broadens the guidance equipment for preoperative positioning: ultrasound, CT, PET / CT and MRI are all applicable, and the application range of preoperative positioning is significantly improved. The positioning accuracy is significantly improved, the surgical resection range can be accurately guided, and the remaining anatomical structure and function of the patient's resected organs are maximized.

The invention belongs to the technical field of small-molecule fluorescent probes, and discloses a high-affinity selective mutant isocitrate dehydrogenase 1 fluorescent probe and application thereof, the structural formula of the fluorescent probe is as shown in formula I, ; in the formula, X1 is a carbon atom or an oxygen atom; x2 is a halide ion or a tetrafluoroboric acid ion; n is 0-5; m is 0-2; r1 and R2 are hydrogen, methyl or ethyl; r3 is an electron donor substituent; r < 4 > is 4-dimethylamino phenyl or 6-dimethylamino naphthyl. The fluorescent probe provided by the invention can accurately identify glioma cells carrying mutant isocitrate dehydrogenase 1 and indicate tumor boundaries, can be used as a targeted fluorescent imaging agent, and has a huge potential of being applied to glioma fluorescence-guided resection.

Methods of producing an incised tissue are presented. The methods may include: contacting a portion of a tissue grasping implement of a first robotic manipulator with a tissue to produce contacted tissue, grasping the contacted tissue using the tissue grasping implement of the first robotic manipulator to produce grasped tissue, and creating an incision in the grasped tissue using a surgical cutting implement of a second robotic manipulator to produce the incised tissue. Additional methods as well as related systems and computer readable media are also presented.

This invention relates to an epileptogenic nodule localization system based on MRI radiomics, belonging to the field of medical informatics. The system includes an image acquisition module, a delineation module, an extraction module, an analysis module, a modeling module, and an optimization module. It extracts radiomics features from the epileptogenic and non-epileptic nodule lesion regions of original MRI T2-Flair images of TSC patients. The preliminary radiomics features are preprocessed, optimized, analyzed, and screened to obtain differential radiomics features between epileptogenic and non-epileptic nodules. A predictive model is established using machine learning algorithms on the obtained differential radiomics features to calculate the radiomics feature score for each lesion, identifying epileptogenic nodules from cortical epileptogenic nodules. This achieves the goal of non-invasive identification of epileptogenic foci in TSC patients, assisting in clinical diagnosis and personalized surgical planning, and enabling precise treatment and surgical resection of epileptogenic foci in TSC patients.

The present disclosure relates to methods for treating a tumor or inhibiting tumor proliferation comprising administering to a cancer patient in need thereof a therapeutically effective amount of a programmed death ligand 1 (PD-L1) inhibitor (e.g., an anti-PD-L1 antibody) as a neoadjuvant therapy followed by surgical resection. In particular, the present disclosure relates to methods for administering a PD-L1 inhibitor as a pre-operative therapy to a patient suffering from resectable upper gastrointestinal cancer (e.g., resectable localized gastric, esophageal or liver cancer). Administration of a PD-L1 inhibitor, in particular an anti-PD-L1 antibody, has proved to exhibit an excellent therapeutic effect as a pre-operative therapy for patients suffering from resectable localized gastric, esophageal and liver cancer.